MedTrace Logo

Apixaban in Subjects With Peritoneal Dialysis

NCT04006093 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-03-27

No results posted yet for this study

Summary

The primary objective of this study is to assess the pharmacokinetics of a single oral dose of apixaban (5mg) in participants with dialysis peritoneal versus participants with normal renal function.

Conditions

  • Chronic Renal Insufficiency
  • Peritoneal Dialysis

Interventions

DRUG

Apixaban single dose 5mg

Apixaban oral single dose 5mg

Sponsors & Collaborators

  • University Hospital, Rouen

    collaborator OTHER

  • University Hospital, Caen

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-08
Primary Completion
2022-12-10
Completion
2022-12-10

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04006093 on ClinicalTrials.gov